Ark gains on hopes for cancer drug
Thursday 31 July 2008
Ark Therapeutics, the gene therapy group, gave the beleaguered UK biotech industry a shot in the arm yesterday when it said that the third phase trial of its brain cancer treatment, Cerepro, has shown good initial results and that it now expects to be able to market the drug by next year.
The company's shares rocketed on the news closing the day up 69 per cent at 80.25p. Ark had earlier said that the topline results of the tests showed that patients using the treatment were on average surviving 42 days longer than people not using Cerepro.
The results come from tests on 183 patients with the company expected to give details of another 53 cases early next year, after which it will apply to European regulators for a licence to sell the drug.
Ibraheem Mahmood, an analyst at Investec, said that while yesterday's news was encouraging, the real tonic for the group is that the positive tests validate Ark's gene based technology and that should lead to interest from some of the pharmaceutical giants. "While the news is certainly good, it is really only a by-product," he said. "Cerepro will be worth between about $500m and $1bn, but it is the first time that the technology has been shown to work and that makes it appealing to buyers."
The news will also be welcomed by the wider UK biotech market, which has a poor record of converting potential drugs in trial into commercial successes. In recent weeks two other groups, Alizyme and Oxford Biomedica, have disclosed pivotal phase three failures, which sent the share price of both companies crashing.
However, the news on Cerepro was not greeted with universal praise. KBC analyst Paul Cuddon pointed out that Cerepro will need to compete against existing medicines. "In order for the trial to be considered a success, and for the company to claim they have a blockbuster, it has to show that it is better than what is already out there, and these trials do not show that," he said. "Ark needed to show that Cerepro is more effective than Temador [another brain cancer treatment] and they have not done that. I still have major concerns."
Mr Mahmood countered that Temador, which had annual sales of $861m last year, has side effects akin to the symptoms suffered by AIDS sufferers, giving patients a poor quality of life.
- 1 Notting Hill Carnival: Woman shares selfie after being ‘punched in face for telling man to stop groping her’
- 2 Keira Knightley topless: Usually conservative actress does own take on #Freethenipple campaign for Interview Magazine
- 3 Daily Show's Jon Stewart destroys Fox News for its Ferguson coverage
- 4 When elitism grips the top of British society to this extent, there is only one answer: abolish private schools
- 5 Terror threat level raised to severe as PM warns Isis risk could last for decades
Keira Knightley topless: Usually conservative actress does own take on #Freethenipple campaign for Interview Magazine
YouTube video posted by Isis militants shows 'execution of 250 Syrian soldiers'
Botched ice bucket challenge leaves man critically injured after plane drops hundreds of gallons of water
Terror threat level raised to severe as PM warns Isis risk could last for decades
Isis 'A Message in Blood' video shows beheading of Kurdish man in Iraq
Robin Williams Emmys tribute led by Billy Crystal criticised for including 'racist' joke about Muslim woman
The Rotherham child abuse scandal is a tale of apologists, misogyny and double standards
Scottish independence TV debate: Pumped-up Alex Salmond bounces back in bruising second round against Alistair Darling
Do you realise just how foolish the UK looks?
Ukip Douglas Carswell defection: Tory MP jumps ship to join Nigel Farage
When elitism grips the top of British society to this extent, there is only one answer: abolish private schools
- < Previous
- Next >
iJobs Money & Business
£50000 - £80000 per annum + benefits+bonus+package: Harrington Starr: Data Sci...
£450 - £500 per day: Orgtel: SAS Business Analyst, London, Banking, Credit Ris...
£32000 - £38000 Per Annum Bonus, Life Insurance + Other Benefits: Clearwater P...
£200 - £250 per day + competitive: Orgtel: KYC Analyst, Key Banking Client, Bi...